ArticleInternational journal of biological sciences2026
Disrupted Estrogen Homeostasis Drives Female-Specific Depressive-Like and Anxiety-Like Behaviors via Convergent ERα Downregulation in the Ventral Hippocampus.
Article in International journal of biological sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although depression exhibits prominent sex differences, mechanisms linking estrogen fluctuations to this vulnerability remain unclear. Here, we reveal that disrupted estrogen homeostasis induces depressive- and anxiety-like behaviors via convergent downregulation of estrogen receptor alpha (ERα) and subsequent neuroinflammation in the female ventral hippocampus (vHPC). In humans (n=6,481), serum estradiol (E2) showed a U-shaped association with depression, increasing risk at both extremes. In mice, while chronic restraint stress (CRS) induced depressive-like behaviors across sexes, it selectively triggered E2 deficiency, anxiety-like behaviors, and decreased vHPC ERα (but not ERβ) in females. Therefore, focusing on females, both supraphysiological E2 (sE2)-induced elevation and CRS-induced E2 deficiency produced depressive- and anxiety-like behaviors converging on vHPC ERα downregulation. Cross-species transcriptomics and multi-omics revealed global concordance between female major depressive disorder (MDD) and both mouse models, identifying ERα as a top upstream regulator associated with neuroinflammation, lipid dysregulation, and synaptic dysfunction. Pharmacological inhibition of ERα exacerbated depressive- and anxiety-like behaviors and neuroinflammation under subthreshold CRS, whereas vHPC ERα overexpression rescued CRS-induced behavioral deficits and neuroinflammatory responses. Integrating human MDD GWAS and PsyGeNET datasets supported this pathway's genetic and clinical relevance. Collectively, we identify vHPC ERα as a unifying therapeutic target for female depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.